Defence, Security, Energy, Utilities, Finance, Pharmaceuticals
Home > Pharmaceuticals > UK

COPD: Novel Therapeutics and Management Strategies

19th October to 20th October 2015, London, United Kingdom

Overview

Open/Close

This event is about the developments made in the field of COPD.
COPD its self-causes 6% of the world’s morbidity and costs the worldwide economy $36 billion.
The disease is chronic and is characterised by a progressive worsening in condition through periods of exacerbation caused by infection and progressive worsening through opportunistic infections.
The disease, though non curable, can be tamed through a range of management mechanisms, such as preventing the development of exacerbations through flu and pneumonia vaccines and early diagnosis and treatment of exacerbations through rapid deployment of antibiotics. Lung function can also be increased and exacerbations reduced through the use of bronchodilators such as corticosteroids and anticholinergic drugs.

 

We look forwards to welcoming you to the 7th Annual COPD Conference 2015 taking place in central London on the 15th-16th October 2015.

The conference will discuss through a range of presentations and panel discussions problems and solutions to COPD treatment options. These include the issues with a blanket approaches being used to treat the disease. COPD is a multifactorial disease with large influences of comorbidity on the clinical progression of  the primary physical COPD disorder. However, in recent years there have been large advances in proteomics and transcriptomics. These advances have allowed for the development of  personalised treatment plans developed for the precise comorbidity. These presonalised treatment strategies will be thoroughly discussed.

This conference will also discuss developing treatments for COPD patients and clinical trials. The time old question in COPD is how one can find a clean patient. The majority of COPD patients are on varying courses of polypharmacy due to a range of different debilitating diseases alongside COPD. The range of different diseases result in great variability in clinical trials data. What is the correct phenotype to measure in the disease?

Our understanding of the pathophysiology in COPD has increased dramatically  thanks to developments in the area of network biology. By understanding the complicated mechanisms by which different aspects of the disease interact it is possible to intervene with crucial nodes progressing the disease. Discussions will be opened on the various models of network biology and biomarkers of the disease to gain a greater understanding of this multifaceted disease.

Finally  the conference will address the advances made in pharmacological treatments. These include advances in combinational therapies and new drugs.

Benefits of Attending

Open/Close

Featured Speakers

Open/Close

Who Should Attend

Open/Close